Call to action for health systems integration of point-of-care testing to mitigate the transmission and burden of sexually transmitted infections.


Journal

Sexually transmitted infections
ISSN: 1472-3263
Titre abrégé: Sex Transm Infect
Pays: England
ID NLM: 9805554

Informations de publication

Date de publication:
08 2020
Historique:
received: 06 11 2019
revised: 25 01 2020
accepted: 19 02 2020
pubmed: 4 4 2020
medline: 12 9 2020
entrez: 4 4 2020
Statut: ppublish

Résumé

In 2016, WHO estimated 376 million new cases of the four main curable STIs: gonorrhoea, chlamydia, trichomoniasis and syphilis. Further, an estimated 290 million women are infected with human papillomavirus. STIs may lead to severe reproductive health sequelae. Low-income and middle-income countries carry the highest global burden of STIs. A large proportion of urogenital and the vast majority of extragenital non-viral STI cases are asymptomatic. Screening key populations and early and accurate diagnosis are important to provide correct treatment and to control the spread of STIs. This article paints a picture of the state of technology of STI point-of-care testing (POCT) and its implications for health system integration. The material for the STI POCT landscape was gathered from publicly available information, published and unpublished reports and prospectuses, and interviews with developers and manufacturers. The development of STI POCT is moving rapidly, and there are much more tests in the pipeline than in 2014, when the first STI POCT landscape analysis was published on the website of WHO. Several of the available tests need to be evaluated independently both in the laboratory and, of particular importance, in different points of care. This article reiterates the importance of accurate, rapid and affordable POCT to reach universal health coverage. While highlighting the rapid technical advances in this area, we argue that insufficient attention is being paid to health systems capacity and conditions to ensure the swift and rapid integration of current and future STI POCT. Unless the complexity of health systems, including context, institutions, adoption systems and problem perception, are recognised and mapped, simplistic approaches to policy design and programme implementation will result in poor realisation of intended outcomes and impact.

Identifiants

pubmed: 32241905
pii: sextrans-2019-054358
doi: 10.1136/sextrans-2019-054358
pmc: PMC7402556
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

342-347

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Expert Rev Mol Diagn. 2017 Sep;17(9):845-859
pubmed: 28741392
PLoS Med. 2017 Jul 7;14(7):e1002344
pubmed: 28686231
Sex Transm Infect. 2017 Dec;93(S4):S22-S30
pubmed: 29223960
Health Policy Plan. 2012 Oct;27 Suppl 4:iv1-3
pubmed: 23014149
Sex Transm Infect. 2017 Dec;93(S4):S31-S35
pubmed: 28684611
Sex Transm Infect. 2017 Dec;93(S4):S65-S68
pubmed: 28684610
Int Health. 2015 Nov;7(6):384-9
pubmed: 26553825
Clin Microbiol Rev. 2014 Jul;27(3):587-613
pubmed: 24982323
BMJ Open. 2017 Jun 14;7(6):e015447
pubmed: 28615273
Clin Chem. 2013 Apr;59(4):629-40
pubmed: 23327782
J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1845-1851
pubmed: 29924422
Sex Transm Infect. 2017 Dec;93(S4):S3-S15
pubmed: 28747410
Sex Transm Infect. 2017 Dec;93(S4):S69-S80
pubmed: 29223965
Curr Opin Infect Dis. 2016 Feb;29(1):45-51
pubmed: 26658656
Int J Gynaecol Obstet. 2015 Jun;130 Suppl 1:S81-3
pubmed: 25983212
PLoS One. 2016 Oct 5;11(10):e0163365
pubmed: 27706174
Lancet Infect Dis. 2007 Jul;7(7):453-9
pubmed: 17597569
Sex Transm Infect. 2017 Dec;93(S4):S16-S21
pubmed: 29223959
Nat Rev Urol. 2017 Mar;14(3):139-152
pubmed: 28072403
Sex Transm Infect. 2017 Dec;93(S4):S81-S88
pubmed: 29223966
Sex Transm Infect. 2006 Dec;82 Suppl 5:v1-6
pubmed: 17151023

Auteurs

Igor Toskin (I)

Department of Sexual and Reproductive Health and Research, WHO, Geneva, Switzerland.

Veloshnee Govender (V)

Department of Sexual and Reproductive Health and Research, WHO, Geneva, Switzerland.

Karel Blondeel (K)

Department of Sexual and Reproductive Health and Research, WHO, Geneva, Switzerland karel.blondeel@ugent.be.
Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.

Maurine Murtagh (M)

The Murtagh Group, LCC, Woodside, California, USA.

Magnus Unemo (M)

WHO Collaborating Centre for Gonorrhoea and Other STIs, National Reference Laboratory for STIs, Department of Laboratory Medicine, Microbiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Charifa Zemouri (C)

College of Dental Medicine, Qatar University, Doha, Qatar.

Rosanna W Peeling (RW)

International Diagnostics Centre, London School of Hygiene and Tropical Medicine, London, UK.

James Kiarie (J)

Department of Sexual and Reproductive Health and Research, WHO, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH